Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is a biotechnology company focused on developing innovative therapies. On March 6, 2026, TVGN executed a reverse stock split at a ratio of 50 for 1. This strategic move was approved by the Board of Directors and aims to help the company meet the Nasdaq Global Market’s $1.00 minimum bid price requirement.
The reverse stock split was approved by stockholders on February 19, 2026, giving the Board the authority to determine the final ratio. As a result, every 50 shares of TVGN’s common stock were automatically converted into one share. This adjustment is intended to consolidate shares and potentially increase the stock price, making it more attractive to investors.
Following the reverse stock split, TVGN’s stock continues to trade under the same symbol but with a new CUSIP number, 88165K 200. The stock is currently priced at $6.84, reflecting a decrease of 11.74% with a change of $0.91. Despite this decline, the reverse split aims to stabilize the stock’s value and maintain its Nasdaq listing.
TVGN’s stock has experienced significant fluctuations, with a daily range between $6.22 and $10.76. Over the past year, the stock reached a high of $75.50 and a low of $6.22. The company’s market capitalization is approximately $27.57 million, and the trading volume for the day is 190,619 shares. These figures highlight the volatility and challenges TVGN faces in the market.
